Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer

NCT00664170 is registered in ClinicalTrials.gov with Mast Therapeutics, Inc. as lead sponsor.

NCT NCT00664170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00664170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
Lead sponsor
Mast Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2008
Completion date
April 30, 2009
Enrollment
39 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer